Skip to main content Skip to main navigation menu Skip to site footer

Lipid and cardiac profile assessment following the co-administration of Cisplatin and methanolic extract of Portulaca oleracea in adult Wistar rats: an experimental study

  • Izuchukwu Azuka Okafor ,
  • Uchenna Somtochukwu Nnamah ,
  • Jude Nnaka ,


Introduction. There is a need for continual evaluation of the effective use of plant-based medicine as combination therapies as more therapeutic potentials are being associated with phytomedicine. The changes in the lipid and cardiac profile of adult Wistar rats following the co-administration of Cisplatin and methanolic extract of Portulaca oleracea (MEPO) were investigated.

Methods. Twenty-four (24) rats with an average weight of 154 kg were randomly divided into six (6) groups (A-F). Group A was given no treatment and served as the normal control group. Group B received only a cisplatin injection and served as the cisplatin control group. Group C and D were given 400mg/kg and 800 mg/kg MEPO six hours after cisplatin injection. Group E and F were administered 400mg/kg and 800 mg/kg MEPO 6 hours before cisplatin injection. All cisplatin injections were single-dose intraperitoneal injection (2 ml/kg) and MEPO administration lasted for 7 days. Animals were euthanized under diethyl ether anesthesia at the end of the experiment and blood collected for serum lipid profile investigations. Some cardiac and lipid parameters were estimated from standard formulae.

Results. There was a significant increase in the serum levels of TG and TC (p=0.01 and p < 0.001) and some estimated parameters – LDL, VLDL, CRR, HDL-LDL and TG-HDL (p<0.001, p=0.049, p<0.001, p<0.001 and p=0.001 respectively) while HTR was significantly decreased (p<0.001) due to cisplatin treatment. HDL and AI levels were unchanged by cisplatin treatment. MEPO significantly reversed (p<0.05) the cisplatin-induced changes in the serum lipid parameters (TG and TC) and estimated parameters (VLDL, CRR and TG-HDL) across all MEPO-treated groups.

Conclusion. MEPO shows evidence of attenuating cisplatin-induced hyperlipidemia and cardiac risk.


  1. Bafna A, Maheshwari RS, Ved RK, et al. Study of Atherogenic Indices in Nephrotic Syndrome. Int J Biol Med Res. 2012;3(3):2257-60.
  2. Cai Y, Luo Q, Sun M, et al. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci.2004; 74:2157-2184
  3. Chan K, Islam MW, Kamil M, et al. The analgesic and antinflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. J Ethnopharmacol. 2000; 73:445451.
  4. Covington M. Omega-3 fatty acids. American Family Physician. 2004; 70 (1):133-140.
  5. Csapo M, Lasar L. Chemotherapy induced cardiotoxicity: pathophysiology and prevention. Clujul Med. 2014; 87(3):135–14.
  6. Cui Y, Blumenthal RS, Flaws JA, et al. Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. Arch Intern Med. 2001; 161(11):1413-1419.
  7. El-Newary SA. The hypolipidemic effect of Portulaca oleracea L. stem on hyperlipidemic Wister Albino rats. Annals of Agricultural Sciences. 2016; 61(1): 111-124.
  8. Ezekwe MO, Omara AT, Membrahtu T. Nutrition characterization of Purslane accessions as Influenced by planting data. Plant Foods Human Nutri (Dordrendit) 1999; 54 (3):183 – 191
  9. Garcia JM, Scherer T, Chen JA, et al. Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology. 2013;154(9):3118-29.
  10. Hanchate LP, Shimpa RS, Sadhana M. Cisplatin Induced Acute Myocardial Infarction and Dyslipidemia. Journal of Clinical and Diagnostic Research. 2017; 11(6): 05–07.
  11. Hojman P, Fjelbye J, Zerahn B, et al. Voluntary Exercise Prevents Cisplatin-Induced Muscle Wasting during Chemotherapy in Mice. PLoS ONE 2014; 9(9): e109030.
  12. Islam MW, Zakaria MNM, Radhakrishnan R, et al. Evaluation of analgesic activities of the aerial parts of Portulaca v. sativa and its comparison with two related species. J. Pharm. Pharmacol. 1998; 50 (S9): 226-226.
  13. Jorge S. Challenges in Routine Clinical Chemistry Testing: Analysis of Small Molecules. Elsevier. 2013; 8:93-129.
  14. Juha P, Shai L, Gerardo H, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New England Journal of Medicine 1990; 322(24): 1700-1707.
  15. Lee A, Lee Y, Lee S, et al. Portulaca oleracea Ameliorates Diabetic Vascular Inflammation and Endothelial Dysfunction in db/db Mice. Evidence-Based Complementary and Alternative Medicine: eCAM. 2012; 741824.
  16. Lim YY, Quah EPL. Antioxidant properties of different cultivars of PO. Food Chem. 2007; 103:734–740.
  17. Liu CJ, Liu DY, Xiang L, et al. Studies on the chemical constituents of PO. JCMM. 2009; 32(11):1689-91.
  18. Madiha F, Hamdy T, Soliman MS, et al. Subchronic Feeding Study of Fenitrothion Residues in Maize and The Protective Action of Purslane (PO L)] Extract on Rats. Journal of Applied Sciences Research. 2012; 8(7): 3688-3696.
  19. Moriel P, Plavnik FL, Zanella MT, et al. Lipid peroxidation and antioxidants in hyperlipidemia and hypertension. Biological Research. 2000; 33:(2).
  20. Movahedian A, Ghannadi A, Vashirnia M. Hypocholesterolemic Effects of Purslane Extract on Serum Lipids in Rabbits Fed with High Cholesterol Levels. International Journal of Pharmacology. 2007; 3: 285-289.
  21. National Research Council (US) Committee for the update of the Guild for the Care and Use of Laboratory Animals. Guild for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US); 2011. Accessed 16th October 2019. Available at
  22. National Health Research Ethics Committee Of Nigeria. Federal Ministry of health. 2014. Accessed 20th October 2019. Available at
  23. Nwagha UI, Ikekpeazu EJ, Ejezie FE, et al. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. African Health Sciences. 2010; 10(3):248-52.
  24. Okafor IA, Ejimofor OC, Ezejindu DN, et al. The Renoprotective Effect of Methanolic Extract of Portulaca Oleracea on Cisplatin-Induced Nephrotoxicity in Wistar Rats. Advances in Life Science and Technology. 2014; 19: 52-60.
  25. Okafor IA, Ezejindu DN. Phytochemical studies on Portulaca oleracea (Purslane) plant. Global Journal of Biology, Agriculture & Health Sciences. 2014; 3 (1):132-136.
  26. Okafor IA, Ezejindu DN, Chukwujekwu IE, et al. Evaluation of the Side Effects of Cisplatin Drug in a Nephrotoxicity Model of Wistar Rats. Journal of Biology, Agriculture and Healthcare. 2014; 4(8):2224-3208.
  27. Radhakrishnan R, Zakaria MN, Islam MW, et al. Neuropharmacological actions of Portulaca oleraceae L v. sativa (Hawk). J Ethnopharmacol., 2001; 76:171-176.
  28. Raghavan D, Cox K, Childs A, et al. hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol., 1992; 10(9):1386–89.
  29. Rasheed AN, Disiam A. Simple evaluation of the wound healing activity of a crude extract of P. oleracea (L) growing in Jordan in Mus musculus JVI-1 J. Ethnopharmacol. 2010; 88:131-136.
  30. Ribeiro, MA, Bernardo-Gell MG, Esquivel MM, et al. Study of antioxidant activity in supercritical residues. J. Supercrit. Fluids 2001; 2: 51-60.
  31. Sharafati R, Rafieian M, Salehi E. Bioactivity of Apium petroselinum and Portulaca oleracea Essential Oils as Natural Preservatives. Jundishapur Journal of Microbiology. 2015; 8(3):20128.
  32. Sharma MM, Singh A, Verma RN, et al. International Journal of Botany 2011; 7(1):103-107.
  33. Wang G, Su C, Yin T. Paclitaxel and platinum based chemotherapy results in transient dyslipidemia in cancer patients. Molecular and Clinical Oncology. 2017; 6:261–65.
  34. Xiang L, Xing D, Wang W, et al. Alkaloids from PO L, Phytochem. 2005; 66:2595–260
  35. Yao X, Kessarin P, Neil K, et al. Cisplatin Nephrotoxicity: A Review. The American Journal of medical sciences. 2007; 334(2):115-124.
  36. Zhu X, Yu L, Zhou H, et al. Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China. Lipids in Health and Disease. 2018; 5;17 (1):37.

How to Cite

Okafor, I. A., Nnamah, U. S., & Nnaka, J. (2020). Lipid and cardiac profile assessment following the co-administration of Cisplatin and methanolic extract of Portulaca oleracea in adult Wistar rats: an experimental study. Bali Medical Journal, 9(3), 799–805.




Search Panel

Izuchukwu Azuka Okafor
Google Scholar
BMJ Journal

Uchenna Somtochukwu Nnamah
Google Scholar
BMJ Journal

Jude Nnaka
Google Scholar
BMJ Journal